13 results about "Testosterone" patented technology

A method and oral composition for treating a plurality of end-stage diseases, such as end-stage renal disease, chronic kidney disease, liver cirrhosis, chronic liver failure, end-stage liver disease, cancer, congestive heart failure, pulmonary fibrosis, and chronic obstructive pulmonary disease, are disclosed. In one embodiment of the invention, the composition comprises testosterone duodecanoate.

The present disclosure relates generally to compositions and methods using ent- testosterone. The disclosed ent-testosterone can be used to inhibit quorum sensing of bacteria. The present disclosure further relates to compositions and methods of treating bacterial infections or having a complicated condition due to bacterial colonization.

This invention discloses the application of a ketone reductase mutant in the catalytic reduction reaction of steroid ketone compounds, belonging to the field of biocatalysis and enzyme engineering technology. The ketone reductase mutant is based on the amino acid sequence of the wild-type ketone reductase ChKRED20, and the following mutations are made: mutant ChKRED20-M4C3: S153L, Q97L, Y188G, and H145A; mutant ChKRED20-M4C5: S153L, Q97L, Y188A, and H145A. This invention provides mutants ChKRED20-M4C3 and ChKRED20-M4C5 that successfully achieve the efficient synthesis of steroid hormones, represented by testosterone. Through carrier-free immobilization technology, efficient recycling and reuse of the ketone reductase mutant are achieved. Based on this, a microfluidic bed is designed to realize the continuous flow production of testosterone.

The application belongs to the technical field of biological medicine, and particularly relates to application of a reagent for inhibiting PPAR alpha expression in preparation of a medicine for treating male infertility diseases, wherein a PPAR alpha inhibitor (GW6471) or an active oxygen scavenger (NAC) is given to male mice exposed to cadmium water, it is found that the number of sperm in a Cd+GW6471 group is higher than that in a Cd+NAC group, the serum testosterone level in the Cd+GW6471 group is also higher than that in the Cd+NAC group, and the results of testicular tissue pathological staining also show that GW6471 can more significantly restore the decrease in the number of mature spermatogenic tubules caused by Cd, GW6471 restores the decrease in the number of SYCP3 positive spermatocytes caused by Cd, so that the sperm production efficiency is restored, and therefore the application of the reagent for inhibiting PPAR alpha expression in preparation of the medicine for treating male infertility diseases is proposed.

This application discloses a nonspecific peroxidase CsaUPO derived from *Cladorrhinum samala*, whose amino acid sequence is shown in SEQ ID NO:1. This enzyme efficiently catalyzes the 4,5β-epoxidation of testosterone to produce 4,5β-epoxidized testosterone, achieving a conversion rate of 98% and a separation yield of 90%, without producing hydroxylation byproducts, and exhibiting excellent regioselectivity. This application also discloses the gene encoding CsaUPO, the recombinant plasmid pPICZA-CsaUPO containing this gene, a recombinant Pichia pastoris engineered strain, and its application in steroid epoxidation. The nonspecific peroxidase CsaUPO disclosed in this application possesses advantages such as high catalytic efficiency, specific regioselectivity, a simple reaction system, and environmental friendliness, providing a new enzymatic resource for the site-directed epoxidation modification of steroid drugs.

This invention relates to the field of biomedicine, specifically disclosing an antibody for treating benign prostatic hyperplasia (BPH) and its applications. The antibody is a nanobody containing a complementary determinant region (CDR) sequence as shown in SEQ ID NO:5. This invention provides a method for preparing the antibody and demonstrates that it effectively antagonizes the binding of GnRH to GnRHR, thereby inhibiting cAMP production mediated by the GnRH signaling pathway and reducing the levels of testosterone, dihydrotestosterone, and luteinizing hormone. In vivo pharmacodynamic experiments show that the antibody provided by this invention can significantly improve the prostate weight / body weight ratio in a rat model of benign prostatic hyperplasia, exhibiting a good therapeutic effect on BPH and providing a new candidate drug for the clinical treatment of BPH.

The embodiment of the application discloses Mfsd2a The application belongs to the technical field of biology and is applied to diagnosing the reproductive capacity of male mammals. Mfsd2a The research results show that, Mfsd2a The deletion results in delayed testis development, testosterone synthesis disorder, spermatogenesis disorder or abnormal testis lipid metabolism in mice, which not only provides a basis for exploring Mfsd2a The gene plays a role in the regulation of livestock reproduction, which provides a new idea for determining the biological function of the gene in the regulation of mammalian reproduction.

The present application relates to a kind of testosterone microcrystal, freeze-dried powder injection, suspension and its preparation method.The particle size range of testosterone microcrystal meets: D90≤20 μm.Testosterone microcrystal freeze-dried powder injection includes testosterone microcrystal, suspending agent and freeze-drying protective agent;The mass ratio of the suspending agent and the mass of the testosterone microcrystal meets (0.3-2):1.The particle size range of the testosterone microcrystal meets: D90≤20 μm.Testosterone microcrystal suspension includes water, testosterone microcrystal, suspending agent and freeze-drying protective agent;The concentration of the suspending agent is 0.3%-2%.The preparation of testosterone microcrystal prepared in the present application is short-acting preparation, has the advantages of small liver toxicity, dose accuracy and easy to use.

This invention relates to the fields of tumor biology and cell engineering, specifically disclosing the construction and application of a human prostate cancer cell line. The human prostate cancer cell line is derived from primary prostate cancer tissue, expresses prostate-specific antigen and α-methylacyl-CoA racemic enzyme, and has a 46,XY karyotype. The construction method employs an innovative strategy of co-culturing fully digested cell suspensions with incompletely digested tissue blocks, significantly improving the success rate of establishing the cell line from the primary lesion. This cell line can stably proliferate in conventional culture media supplemented with testosterone and has been successfully applied to subcutaneous tumorigenesis models in immunodeficient mice and in vivo migration models in zebrafish. The primary lesion-derived prostate cancer cell line provided by this invention offers a highly relevant, stable, and reliable new experimental tool for studying the biological characteristics of primary prostate cancer, drug screening, and personalized treatment.

This invention, entitled "A Fertilization Culture Medium, Its Preparation Method, and Its Application," belongs to the field of assisted reproductive technology. The technical problem it aims to solve is that existing technologies, due to the generation of sperm DNA fragments during the culture process, lead to a decrease in overall sperm quality, limiting fertilization rate and blastocyst formation rate. This invention proposes a fertilization culture medium that can improve overall sperm quality and thus increase fertilization rate. The key technical points are: a fertilization culture medium comprising the following components: sodium chloride, potassium chloride, alkali metal dihydrogen phosphate, calcium chloride, magnesium sulfate, sodium bicarbonate, sodium lactate, sodium pyruvate, glucose, fructose, disodium edetate, gentamicin, human serum albumin, alanylglutamine, taurine, non-essential amino acids, and testosterone.

The present invention relates to a method of preparing a novel acetic acid testosterone. The present invention further relates to a novel acetic acid testosterone, preferably obtained by the method of the present invention. The present invention further relates to a method of preparing a testosterone derivative and / or a testosterone derivative for labeling, preferably prepared from said acetic acid testosterone. The present invention further relates to the testosterone derivative and / or a testosterone derivative for labeling, preferably obtained by the method of the present invention, as well as to the use of the testosterone derivative and / or a testosterone derivative for labeling, for radiolabeling with diagnostic and / or therapeutic radionuclides and the medical uses.

The Mogroside extract has the effect of improving the damage of the heat stress boar's reproductive capacity. Research shows that, in the process of heat stress of boar, by adding Mogroside extract in the basic diet, the damage of reproductive capacity caused by heat stress can be effectively improved. The test data shows that the Mogroside extract can significantly improve the sperm density, effective sperm number, sperm motility and reduce the sperm abnormality rate of boar; significantly increase the content of a-glucosidase, lactate dehydrogenase, acrosome enzyme and hyaluronidase in the semen, and increase the concentration of testosterone in the serum, enhance the energy supply, structural integrity, functional maturity and fertilization capacity of sperm. Therefore, the Mogroside extract has the potential for further development in the treatment and prevention of heat stress boar's reproductive capacity damage, and can be used for preparing the medicine for improving the heat stress boar's reproductive capacity, so as to further develop the health care function and medicinal value of Siraitia grosvenorii.